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Original Article
Sulforaphane from Broccoli Reduces
SymptomsofAutism:AFollow-upCaseSeries
from a Randomized Double-blind Study
Rhoda Lynch*,1, Eileen L Diggins, BA1, Susan L Connors, MD1,
Andrew W Zimmerman, MD1,2,3,4,5, Kanwaljit Singh, MD, MPH1,
Hua Liu, MS, PhD6,7, Paul Talalay, MD6,7, and
Jed W Fahey, MS, ScD6,7,8,9
Abstract
Introduction: Autism spectrum disorder (ASD) affects 1 in 68 children, is characterized by impaired social interaction and
communication as well as restricted or repetitive behaviors, and varies widely with respect to its causes and presentations.
There are no validated pharmacologic treatments for the core symptoms of ASD. The social, medical, and economic burdens
of ASD on families and caregivers are profound. We recently showed in a small clinical trial that sulforaphane (SF) from
broccoli sprouts could significantly reduce the behavioral symptoms of ASD.
Methods: After we completed the intervention phase of the original trial (2011–2013), many caregivers used over-the-
counter dietary SF supplements in order to attempt to maintain improvements similar to those noted during the interven-
tion. We periodically followed the progress of study participants through the summer of 2016.
Results: Families of 16 of the 26 subjects who received SF as part of the original study responded to requests for further
information. Of these subjects, 6 did not continue taking SF supplements after the study. Nine of the 16 subjects are still
taking an SF supplement and a 10th planned to. We present the edited testimonials of their caregivers in this case series.
Conclusions: Many parents and caregivers articulated the positive effects of SF, both during the intervention phase and in
the ensuing 3 years reported herein. These observations may contribute to understanding ASD and to treatments that may
alleviate some of its symptoms. Diet- and supplement-based therapies deserve careful consideration for their potential to
provide vital clinical as well as biochemical information about ASD.
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Introduction
‘‘Knock-knock. . . who’s there? Knock-knock. . . who’s
there? Knock-knock. . . who’s there? It was like he was
stuck.’’ Before he was 27 months old, ‘‘R’’ was a
typically developing child and was easily able to finish
telling his favorite knock-knock joke; but after an illness,
his social and behavioral development halted, and he was
soon diagnosed with autism (Autism Spectrum Disorder
[ASD]). ASD is now estimated to affect 1 in 68 children
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in the United States by age 8 years,1 and it exacts major
emotional, financial, and social costs on the families of
these children throughout their development, which con-
tinue into adulthood.
There is no cure for ASD, and despite advances in
clinical therapies, there are no validated pharmacologic
treatments for the core symptoms of ASD. Physicians
often prescribe atypical antipsychotics to treat irritability
and aggression in persons with autism. Aripiprazole
(Abilify) and risperidone (Risperdal) are the only 2
medications currently approved in the United States by
the U.S. Food and Drug Administration (FDA) to treat
ASD. However, side effects of these drugs include extra-
pyramidal symptoms and can pose considerable risks
such as dyskinesias (disorders in which involuntary tics
and tremors occur), gynecomastia, and fatigue; increased
appetite resulting in weight gain and obesity; and
increased risk for diabetes. Further, due to CYP2D6
polymorphisms and variations in drug metabolism, pre-
dicting the frequency and magnitude of these side effects
is difficult.2,3
Sulforaphane (SF; 4-methylsulfinylbutyl isothiocyan-
ate) was isolated by Drs Paul Talalay and Yuesheng
Zhang in 1992 at the Johns Hopkins University
School of Medicine4 and has since been studied exten-
sively for its ability to prevent or delay the onset of
various forms of cancer. SF is the chemoprotective,
anti-inflammatory phytochemical that is prepared
from broccoli sprouts5 and has been successfully admin-
istered in a number of small clinical studies as diverse
as cancer prevention, asthma, pulmonary function,
alcohol toxicity, cognitive function, gastric colonization
with Helicobacter, and ASD. SF-rich dietary supple-
ments started to come on the market soon after our
1997 publication,5 and they have proliferated in
number and form ever since. There are now supple-
ments rich in SF, many that are rich in glucoraphanin
(GR; the biogenic precursor of SF), or in GR with
myrosinase (MYR; the enzyme responsible for convert-
ing precursor to active moiety) (Figure 1). Some of
these supplements were used by subjects following the
intervention phase in our clinical trial of SF in ASD
(see below) and in relating their observations, we have
herein substituted trade names with the phrase ‘‘BSE,’’
an acronym for broccoli sprout [or seed] extract.
A potential mechanistic connection between ASD
symptoms and SF was identified based upon the wide-
spread observations by families that improvement in
ASD symptoms can be associated with a febrile illness
in about 35% of patients.8 This had been clinically vali-
dated by Curran et al.9 Since SF had been previously
shown to trigger a cellular heat shock response,10–13 simi-
lar to the effects of fever, we felt that there might be
an effect of SF on ASD symptoms. Thus, between
2011 and 2013, we conducted a small clinical study
(NCT01474993) designed to assess whether SF would
reduce or ameliorate the behavioral symptoms that are
typical of individuals with ASD.8,14,15 The published
study evaluated behavior in 44 young men with
ASD between the ages of 13 and 27 years. In this
Figure 1. Conversion of glucoraphanin to sulforaphane. The enzyme myrosinase rapidly converts glucosinolates to their cognate iso-
thiocyanates upon mastication of the plant tissue by humans. Myrosinase is found in cruciferous vegetables (eg, broccoli, wasabi, mustard,
or radish) and also in human gastrointestinal flora. It is this latter source which is of most critical importance when human beings eat
cooked broccoli or other cruciferous vegetables since cooking/heating inactivates myrosinase. The effects of sulforaphane on a variety of
biochemical and molecular biomarkers and their clinical and preclinical applications have been recently reviewed6,7.
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double-blind randomized, placebo-controlled study, 26
participants randomized to SF received a weight-
adjusted daily dose for 18 weeks, and 14 participants
received a placebo. Behavior was monitored using stan-
dardized behavioral metrics as described previously8: the
caregivers or parents completed the Aberrant Behavior
Checklist (ABC) and Social Responsiveness Scale (SRS),
and the physicians completed the Autism Clinical Global
Impression Severity (ACGI-S) and Autism Clinical
Global Impression Improvement (ACGI-I) scales
before the intervention, at the 4th, 10th, and 18th
weeks of intervention, and then 4 weeks after discontinu-
ing SF or placebo.
Of the 26 participants who were taking SF throughout
the study, 17 (65%) improved significantly, most of
whom returned to baseline levels 4 weeks after terminat-
ing the intervention. None of those on placebo had chan-
ged significantly. Individuals randomized to take SF
showed improvements in aberrant behavior (measured
using the ABC scale) and in social responsiveness (mea-
sured using the SRS scale), with a significant decrease in
irritability, hyperactivity, and stereotypy. Over the
course of the 18-week study, there was a significant
increase in communication (as measured by the SRS
scale) and an overall improvement on the ACGI-I.
At the conclusion of this study, many parents or care-
givers expressed interest in their sons with ASD continu-
ing to receive BSE. We ultimately suggested a small
number of commercial nutritional supplements which
we had tested to verify that the retail products had
levels of active ingredients (SF or its precursor, GR;
see Figure 1) close to that which was specified on their
labels. Direct comparisons of these products are compli-
cated by the fact that some contain SF and others
contain its more stable but biologically inactive precur-
sor, GR (Figure 1). Generally, bioavailability of the
GR-rich product averages about 10%, that of GR plus
MYR averages about 35%, and for SF-rich BSE it is
about 70%, but there is considerable person-to-person
variability in bioavailability of any and all of these
preparations.16,17
Methods
As reported by parents and caregivers of ASD partici-
pants, taking an SF-rich supplement had resulted in
improved social responsiveness and communication
and had lessened some ASD symptoms such as irritabil-
ity and motor stereotypies.8 This was consistent with
anecdotal evidence that we continue to receive from
people in the ASD community who are familiar with
our study and have used various SF preparations.
Caregivers of subjects from our published study contin-
ued to communicate with us after their formal enroll-
ment in trial had ended and the study results
published.8 One of us (AWZ) called each subject’s
parent or caregiver in January 2014 to formally ensure
accuracy of all follow-up responses, and those comments
were confirmed and in some cases updated in the
summer of 2016 as we put this manuscript together.
There was no prompting for responses. We collected
details for presentation herein, as an anecdotal case
series. The 4 groups (a–d) into which we have
categorized their responses were drawn up ex post
facto, only after comments had been assembled and
not by those who received the responses from care-
givers. Of the 44 participants’ families in the original
study (males from ages 13 to 27 years with moderate
to severe ASD) 17 of 26 on SF improved8; and 14 of
these 17 continued to respond to follow-up questions
regarding their progress. Two of the nonresponding
subjects on SF also participated in further follow-up.
Informed consent was provided by all study partici-
pants and/or their caregivers with whom we remained
in contact under Protocol # 2011-P-002221/1 by the
Partners Human Research Committee at the
Massachusetts General Hospital, IND 113542 from
the FDA, and NA_00068112 by the Johns Hopkins
Institutional Review Board (IRB). A total of 16
families/caregivers responded, and summaries of those
responses are reported.
Results
Responses of the 16 families or caregivers fell into 4
categories. Their sons: (a) experienced no major behav-
ioral changes during the study (n¼ 3), (b) experienced
lasting behavioral changes after administration of the
SF supplement and no longer take it (n¼ 1), (c) they
are unsure whether to continue their son on SF because
of recent health issues (n¼ 2), or (d) are either still taking
SF (n¼ 9) or looking to acquire alternative SF supple-
ments (n¼ 1) (Figure 2).
We begin with an extended narrative from one
family about their son whom we have called ‘‘R.’’
This is followed by briefer descriptions in accord
with the outline (a–d) above. The caregivers’ responses
are paraphrased, and fictitious single initials are
utilized to protect subjects’ identities. Responses are
truncated or paraphrased herein, and full transcripts
are provided as supplemental digital content (see
Supplementary Material, Results).
R’s Story
R’s parents wanted to help him: ‘‘He would make con-
stant noises and did all these abnormal motor tics; [we]
felt like he really had no control [over his behavior and
body] and it was just noise, not functional words.
He didn’t have any expressive language.’’ R’s parents
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saw several medical specialists who prescribed a total of
18 different medications, all of which had either minimal
or negative effects on R. ‘‘Nothing changed the constant
noises or the terrible rage attacks,’’ until R took SF.
R had taken risperidone, then aripiprazole, but his
parents quickly stopped these medications when they
realized that they were having negative impacts on
their son. On risperidone, R was unable to sleep and
became constipated. On aripiprazole, there were
improvements in R’s sleep pattern, but as soon as he
stopped taking it, he began experiencing motor tics.
R’s family took him to the Lurie Center at
Massachusetts General Hospital where we were conduct-
ing the study on the effects of SF on males with ASD.8 The
study was a randomized double-blind placebo-controlled
trial. However, within days, R’s mother believed that he
was taking SF: ‘‘I knew that he was on the study drug
because I saw such a change so quickly. I want to scream
from the rooftops and tell people to give the kids broccoli
sprouts [extract] because literally, it changed my life,’’
reported R’s mother. ‘‘Now we can go to the movies, res-
taurants, plays, we went on vacation with another family,
we go to church, we just went to a concert, things we could
never do before are now possible. [I am] able to have con-
fidence and he [R] is more confident as well.’’
N.B. Such a rapid response was unusual in the context
of what was observed by the study physicians with other
subjects. When responses to supplementation were
observed, they generally took 3 or 4 weeks to become
manifest. In this case, the study team actually wondered
whether the mother might be exhibiting a placebo
response; however, the ABC subscales and both ABC
and SRS overall scores for R did also change.
Summarized Case Reports
A. Three participants who took SF did not appear to
improve during the study. Their parents reported
lack of a noticeable effect and were not aware
Figure 2. Patient Flow for Follow-up Interviews. SF, sulforaphane.
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whether their young adults had been taking SF or
placebo.
B. One participant no longer uses SF. However, he
improved dramatically while taking it during the
study and remained ‘‘improved’’ after the study, sug-
gesting to the study team a possible ‘‘epigenetic
switch’’ might have been triggered.
‘‘W is doing fantastic. He really turned into the most
relaxed and fantastic child (on sulforaphane). Definitely
something great. Helped him a lot. His friends, family,
and members at his home all noticed a wonderful
change. He is off the sulforaphane and has been since
the end of his study in 2012.’’
C. Two caregivers treated their sons with a BSE supple-
ment and later took them off (n¼ 2):
a. ‘‘I would like J to go back on the BSE. I have
observed a decrease in his eye contact, attention
and verbalizing. This could be due to the new
medication (levetiracetam) or discontinuing the
supplement(?)’’ [see Supplementary Material.]
b. ‘‘During the study we did see some improvements,
mainly his temperament was more even and there
were some gains in language. After the study we
continued on a sulforaphane supplement and B
appeared to do well.’’ [The improvements dimin-
ished off the supplement, see Supplementary
Material.]
D. Parents of 10 participants reported that their sons are
still taking, or plan to take a sulforaphane or a glu-
coraphanin supplement [BSE]:
a. ‘‘We felt that the broccoli did help our son J have
more language. That decreased after the study
ended.’’
b. ‘‘Z continues to take a supplement. Prior to par-
ticipation in the study, Z had been a fingernail
picker, meaning I did not have to trim his finger
or toenails for at least 10 years because he would
pick at them (keeping them short). Three weeks
into the study, I realized that Z’s nails needed
trimming! And I have had to trim them regularly
since, as Z no longer picks at them. My husband
and I do feel that Z is a little more verbal, but it is
hard to measure that.’’
c. P (A nonverbal young adult)—‘‘. . . is in a group
home and comes home every other weekend. The
first weekend home after he started the study I
noted a change. He was calmer, seemed happier,
less stressed. His focus was improved. His group
home manager had the same comments about P.
She has worked with him since he was 6 years old.
I can best describe it as he gained a level or two
and it covered all areas; the house manager was in
total agreement.’’
d. ‘‘One of the biggest differences before the study
was that he would bite and rip off his shirt. And
during the study, he stopped that behavior and it
started up again when he was off the sulfora-
phane. When he was on the sulforaphane, he
was more calm and more responsive. M’s inter-
actions are more intentional than before.’’
e. ‘‘He (T) is still on it [BSE]. It’s amazing. . . I don’t
know what it is. It’s almost like voodoo or magic
but he is definitely better and he has made
improvements.’’
f. [Parent of one of the earliest participants—in
2012]—‘‘Before the study, our son utilized
speech only for his wants and needs. He did not
engage in casual conversation. He did not social-
ize. His verbal ability was considered ‘low’ for his
age. Within the first month, [after starting study]
his teachers noted his speech increasing and his
willingness to socialize improving. He began to
use articles and prepositions which he had not
utilized before. . . He verbally engaged with our
family more than ever before. He initiated casual
conversation for the first time. He asked how we
felt, what we were doing, and if we needed help
(none of which he had done before the study). He
showed interest in others, outside of himself.’’
g. ‘‘R is now happier, has more control over his
body, and overall is a positive child with a great
attitude. He is more social and goes to concerts,
movies, restaurants, vacations, and family outings
(all of which were not possible before the study).’’
h. ‘‘X is still on sulforaphane and doing well.’’
i. J’s parents have frequently expressed wonderment
to study physicians regarding the effects of SF on
their son, who continues to take a BSE
supplement.
j. Son is doing well (and has recently increased BSE
intake).
The clinical team, now at the University of
Massachusetts Medical School, is currently conducting
another clinical trial of SF in 50 boys and girls with
ASD, aged 3 to 12 years, (NCT02561481), using a proto-
col similar to the previous study in young men. In add-
ition to looking for changes in the symptoms of ASD,
their collaborators at Johns Hopkins University are eval-
uating biomarkers in blood samples taken before,
during, and after this intervention. They will investigate
the molecular mechanisms by which SF brings about
changes at the cellular level.
Discussion
The effects of SF supplementation appear clear and
powerful to many caregivers. Their reports are striking.
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However, as is usually the case with anecdotal reports,
they do not carry the same weight as results from
randomized controlled trials or other prospective inter-
ventional studies. But, such case histories, chart reviews,
and field notes can inspire and instruct formal clinical
trials. In this case, they have helped to inspire at least 5
follow-on studies of SF in ASD of which we are
aware (NCT02561481, NCT02677051, NCT02909959,
NCT02654743, and NCT02879110), and 2 related
studies on alleviation of symptoms of schizophrenia
(NCT02880462 and NCT02810964).
Commercial sources of the broccoli phytochemicals
GR, MYR, and SF are deliberately not mentioned in
this article. There are now a large number of products
and manufacturers. These manufacturers recommend
usage (their label instructions for taking their products)
that would theoretically produce a huge range of doses
of active ingredient (about 10-fold) if active ingredient
content is truly that which is indicated on the labels. We
know that between-individual variation in bioavailability
(of a known, standardized dose) is also marked. There is
no consensus on the appropriate dose for an enhanced
healthspan. To the degree that there is any efficacy for
specific medical conditions, one can infer an approxi-
mate efficacious dose guided by our studies and those
of others, but we do not have reliable data on where
this dose lies. Our testing of the few products we ultim-
ately recommended to former participants suggests that
they do contain what they say they contain, but there are
a great many more which we have not tested. There are
also many such products that we have tested which do
not contain the levels of GR or SF that they claim to
contain.
The emotional and economic burdens on the families
and caregivers of children and adults with ASD are enor-
mous. In many respects, these caregivers are also in the
best position to evaluate ASD symptoms. Evaluation
scales such as the ABC depend upon parents’ or teachers’
observations. Thus, regardless of the fact that any anec-
dotal evidence elicits disagreements among clinicians
over the validity of the observations, it is clear that: (a)
ASD cannot be diagnosed as definitively as a fractured
leg or an arterial stenosis and (b) if caregivers sense a
reduction in symptom intensity, there is direct benefit
(to them) that may have intrinsic value. We believe
that discussions of the role that nutritional or other
‘‘supplements,’’ such as cruciferous vegetables them-
selves, or the SF-rich and glucoraphanin-rich supple-
ments, can play in the lives of individuals with ASD, is
a worthwhile and necessary conversation to have with
caregivers. It is also likely that nutritionally based inter-
ventions, with demonstrated clinical efficacy, can also
contribute to new knowledge about the underlying meta-
bolic pathways that contribute to ASD. We present these
case histories in the hope of learning better ways to treat
ASD safely and effectively, and stimulating others to
do so, thus enhancing the healthspan of the increasing
numbers of children that are diagnosed as they progress
through life.
Informed consent was obtained under Protocol #
2011-P-002221/1 (Partners Human Research
Committee at the Massachusetts General Hospital),
IND #113542 (FDA), and NA_00068112 (Johns
Hopkins IRB).
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